Komori, Osada, Tanaka, Takahashi, Nagao, Yamaguchi, Asano, and Yoshida: A case of esophageal adenocarcinoma arising from the ectopic gastric mucosa in the thoracic esophagus

A case of esophageal adenocarcinoma arising from the ectopic gastric mucosa in the thoracic esophagus

Abstract

A 75-year old man was detected with a pediculate tumor in the upper esophagus. A biopsy determined that it was an adenocarcinoma. A subtotal esophagectomy with dissection of three-fields of lymph nodes was selected. The pathological study revealed it to be an esophageal adenocarcinoma arising from ectopic gastric mucosa of the fundus of the stomach. His post-operative course was uneventful and without sign of recurrence for 3.5 years.




Introduction

Esophageal adenocarcinomas arising from ectopic gastric mucosa (EAEGM) have been reported in only 26 cases worldwide, therefore therapy for this condition is still inconsistent. The available therapeutic strategies for surgical treatment, chemotherapy and/or radiation will be discussed from experience with the present case, and in reference to past reported cases. This is the first report to discuss the clinical features and treatment for EAEGM.

Case Report

A 75-year old man underwent a medical examination without any complications. Since an upper gastrointestinal X-ray showed a simple shaped tumor, 20 mm in size (Figure 1a), detailed studies were selected. On laboratory blood examination, no abnormal data were found except for slight anemia and a high value of squamous cell carcinoma-related antigen, 1.3 ng/mL (normal range; <1.5 ng/mL). An upper gastrointestinal endoscopy detected a pediculate tumor, 25 mm in size, with easy bleeding in the upper thoracic esophagus (invasive level; muscularis propria) (cT2) (Figure 1b), and pathological findings from a biopsied specimen revealed a moderately differentiated tubular adenocarcinoma. With chest and abdominal computed tomography (CT), a primary pediculate tumor, 30×20 mm in size, with regional lymphnode swelling (N1) was noted without any metastasis or direct invasion to other organs (M0). According to the UICC 6th edition staging system, the tumor was indicated as cStage IIB, and a subtotal esophagectomy with lymph-node clearing was performed in April, 2006. On removal, a type I tumor, 35×22 mm in size, was observed on the esophagus, and it stained negative with lugol solution (Figure 2). In addition, the esophageal mucosa surrounding the tumor was also negative for lugol solution, suggesting that the tumor arose from the ectopic mucosa. The pathological study demonstrated the presence of a tubular papillary and solid type EAEGM (pStage: I, invasion level: mucosa, lymphatic duct invasion: not detected, vessel invasion: not detected) (Figure 3), and lymph node metastasis was not noted. The patient is currently in good health without any problems.

Figure 1

Upper gastrointestinal X-ray and endoscopic examination. Barium esophagogram (a) (arrow) and upper gastrointestinal endoscopy (b) showed a pediculate tumor, 20 mm in size, which was detected in the upper thoracic esophagus.

rt-2010-1-e5-g001.jpg

Figure 2

Removed specimen of subtotal esophagectomy. The type I tumor, 35 × 22 mm in size, was detected in the specimen (arrow head). The tumor was round shaped and was negative for lugol solution staining, with the negative staining extending 5 cm distant from the oral margin (arrows).

rt-2010-1-e5-g002.jpg

Figure 3

Pathological findings. Tubular, papillary and solid adenocarcinoma were localized within the tumor (a and b). In the epithelium around the tumor, mucosa similar to fundic gland mucosa extended from the tumor (a and c). H & E stain, (a) ×40, (b and c) ×100 magnification.

rt-2010-1-e5-g003.jpg

Discussion

Primary esophageal adenocarcinomas that match the following diagnostic criteria represent 0.76% of all the cases of carcinoma of the esophagus or cardia; i) a tumor localized in the esophagus from the cricoid cartilage to the cardiac orifice; ii) a tumor arising from the esophageal glands; iii) a tumor that has tissues of the glands, and where there are lesions of the carcinoma discharging mucus on the inside of the tumor; iv) existence of normal squamous epithelium in the anal side of the tumor, or a tumor that exists in an area apart from the cardiac orifice; v) no primary cancerous lesions in the other organs.1,2 Because the incidence of ectopic gastric mucosa has been detected in only 4.0% of males and 2.9% of females,3 carcinogenesis at this site is observed quite rarely, with 26 cases reported worldwide as shown in Table 1.425 The age of these patients ranged from 37 to 85 years, and the tumor size was between 1.9 and 7.0 cm (mean; 3.9 cm). The nature of invasion into surrounding tissues was found to be to the submucosal level in 9 cases, muscular invasion in 4 cases and advanced invasion in 9 cases, with 3 cases unknown. If the degree of layer invasion and tumor size are compared, the average tumor size was 3.4 cm in submucosal invasion, 4.3 cm in advanced invasion and 4.5 cm in muscular invasion, suggesting that the tumor size (width of growth) might be associated with the degree of layer invasion (invasive level of tumor). However, the prognosis was not exactly indicated by tumor size, because in patients with big tumors, such as 5 cm or 6.5 cm, there may be no signs of recurrence, whereas tumors as small as 2 or 3 cm could lead to recurrence. Focusing on the nature of the layer invasion to estimate the most favorable therapeutic strategy in submucosal invasion cases, esophagectomy was an appropriate radical treatment, but not partial resection, because local resection alone was found to lead to local recurrence. In muscular invasion cases, one of 2 cases of esophagectomy without additional therapy led to recurrence, and a case treated with radiotherapy (RT) and chemoradiotherapy (CRT) showed a relatively good prognosis. In advanced cases, with the exception of one unknown case without detailed data, esophagectomy without additional therapy led to a poor prognosis for 3 cases in 4, and one case remains alive but is still under short-term observation. In contrast, one esophagectomy case combined with RT showed a good outcome. In addition, esophagectomy combined with radiation or chemo-radiation therapy might result in a favorable outcome, suggesting that additional treatment beyond the initial operation is critical. In the present case, since there was no tumor invasion into the muscular layer, no adjuvant treatment was required and no signs of recurrence have been observed.

Table 1

Twenty-six cases of esophageal adenocarcinoma arising from the ectopic gastric mucosa.

Author and year Age/sex Size(cm) Histological type Depth of invasion Treatment Prognosis
1. Carrie (1950)6 64M 3 Adenoca. Muscularis propria Partial esophagectomy Alive (over one year; unknown in detail)
2. Davis (1969)6) 68M 1.87 Mucinous adenoca. Submucosa RTesophagectomy Alive (7 months; unknown in detail)
3. Sakamoto (1970)7 64M 2.51.7 Papillary adenoca. Muscularis propria RTesophagectomy and inguinal skin meta) Dead (37 months; cervical
4. Clemente (1974)8 53M 2.522 Intestinal type. Adventitia Laryngectomy esophagectomy Cervical recurrence
5. Danoff (1978)4 43M 6 Poorly diff adenoca. Adventitia RT Dead (2 months)
6. Kamiya (1983)9 58M 53 Moderately diff adenoca. Adventitia Pharyngolaryngectomyesophagectomy Dead (7 months; pneumonia)
7. Schmidt 1 (1985)10 37M Not mentioned. Adenoca. Adventitia Esophagectomy Alive (4 months; unknown in detail)
8. Schmidt 2 (1985)10 54M 3 Adenoca. Submucosa Partial esophagectomy Dead (12 months; local recurrence)
9. Endo (1986)11 73M Not mentioned Adenosquamous ca. Unknown Not resected Dead (12 months)
10. Christensen 1 (1987)12 52M 65.52 Poorly diff adenoca. Muscularis propria Esophagectomy Dead suspected (Abdominal meta)
11. Christensen 2 (1987)12 50M 43.51.5 Moderately diff adenoca. Adventitia Esophagogastrectomy Not mentioned
12. Ishii (1991) (13) 66M 54.53 Well diff adenoca. Submucosa Esophagectomy No rec (20 months)
13. Kubota (1993)14 58M Not mentioned. Papillary adenoca. Adventitia CRT only Dead (12 months; lung meta)
14. Takagi Y (1994)15 85M 6.83 Moderately diff adenoca. Adventitia Transhiatal esophagectomy Not mentioned
15. Takagi A (1995)16 70M 1.91.6 Well diff adenoca. Submucosa Esophagectomy Not mentioned
16. Sperling (1995)17 79M 2 Poorly diff adenoca. unknown RT Not mentioned
17. Kammori (1996)18 74F 21.50.7 Well diff adenoca. Submucosa Mucosal resection No rec. (unknown in detail)
18. Pai (1997)19 60M 3.56.5 Moderately diff adenoca. Muscularis propria EsophagectomyCRT Alive (30 months; unknown in detail)
19. Berkelhammer (1997)20 71M Not mentioned Moderately diff adenoca Submucosa Esophagectomy No rec. (2 years)
20. Yamamoto (1997)21 90F Not Adenoca. unknown Transhiatal esophagectomy Not mentioned
21. Lauwers (1998)22 57M 24 Moderately diff adenoca. Adventitia EsophagectomyRT Alive (8 months; unknown in detail)
22. Noguchi (2001)23 73M 2.52 Well diff adenoca. Submucosa Esophagectomy No rec (5 years)
23. Kagawa (2001)24 51M 22 Moderately diff adenoca. Adventitia Esophagectomy Dead (11 months; lung meta)
24. Abe (2004)25 50M 2.51.5 Well diff adenoca. Submucosa Esophagectomy No rec (unknown in detail)
25. Alrawi (2004)5 60M 3.23 Moderately diff adenoca. Submucosa Partial esophagectomyCRT No rec (6 years)
26. Our case (2006) 75M 3.52.2 Adenoca. Mucosa Esophagectomy No rec (42 months)

[i] Adenoca, adenocarcinoma; rec, recurrence; meta, metastasis.

The rate of lymph node metastases was found to be relatively high in the esophagus, with around 30% of cases showing submucosal invasion, compared to 19% in the stomach.26 Additionally, distant metastasis has been noted frequently due to the anatomical characteristic of the esophagus developing a strong lymphatic network,27 indicating the importance of aggressive lymph node resection. In fact, complete surgical resection represents a first-line treatment for esophageal adenocarcinomas, such as Barrett's esophageal adenocarcinoma.28 In addition, in East Asia, the combined drug TS-1 (tegafur/gimeracil/oteracil potassium), an oral 5-FU drug, is widely accepted as a chemotherapeutic agent due to its high response rate; 47% in single use and over 70% when used in combination with other chemotherapeutic agents.29,30 In contrast, because TS-1 is not commonly used in North America and Europe, a combination chemotherapy based on infused 5-FU is widely selected as a standard; infused 5-FU and cisplatin or the addition of a third drug (anthracyclines; epirubicin).31,32 The response rate has been reported as 49–56% against locally advanced gastric cancer.33,34 In conclusion, radical surgical treatment with adjuvant chemotherapy should be considered for advanced EAEGM.

References

1 

T Nakayama, F Yanagisawa, K SuzukiPrimary adenocarcinoma of esophagusJapan Journal of Cancer Clinics196410816

2 

HA Raphael, FH Ellis Jr, MB DockertyPrimary adenocarcinoma of the esophagus: 18-years review and review of literatureAnn Surg199616478596

3 

H Nakajima, A Munakata, Y YoshidaEndoscopic diagnosis and significance of islet patchGastroenterological Endoscopy199133135762

4 

B Danoff, J Cooper, M KleinPrimary adenocarcinoma of the upper oesophagusClin Radiol19872951922

5 

SJ Alrawi, J Winston, D TanPrimary adenocarcinoma of cervical esophagusJ Exp Clin Cancer Res20052432530

6 

WM Davis, MN Goodwin Jr, HC Black Jr, JC HawkPolypoid adenocarcinoma of the cervical esophagusArch Pathol19698836770

7 

G Sakamoto, K Nakamura, M Saito, T SugaharaPrimary adenocarcinoma arising from heterotopic gastric glands of esophagusJapanese J Cancer Clinics197016110510

8 

C ClementeUn caso di adenocarcinoma del terzo superior dell esophago insorto su etropia gastricTumori1974601724

9 

J Kamiya, H Ishigure, M AkitaA case of primary adenocarcinoma of the cervical esophagus arising from ectopic gastric mucosaJapanese J Gastroenterol Surgery198916180811

10 

H Schmidt, R RiddelAdenokarzinoma in heterotoper magenschleimhaut des proximaen ösophagusLeber Magen Dram1985151447

11 

T Endo, Y TanakaThe study of the patient suffered from the ectopic gastric mucosa with interesting endoscopic findings and unique courseGastroenterol Endoscopy19862832743274

12 

WN Christensen, SS SternbergAdenocarcinoma of the upper esophagus arising in ectopic gastric mucosa. Two case reports and review of the literature.Am J Surg Pathol198711397402

13 

K Ishii, H Ota, J NakayamaAdenocarcinoma of the cervical oesophagus arising from ectopic gastric mucosaVirchow Arch A Pathol Anat Histopathol199141915964

14 

S Kubota, H Yamaguchi, K ShiraoA case of adenocarcinima of the cervical esophagus arising from heterotopic gastric mucosaGastrointest Endosc19935125560

15 

Y Takagi, S Sato, K KimuraA case of primary intra-thoracic esophageal adenocarcinoma in ectopic gastric mucosa in an elderly patientJ Jpn Surg Association1994553904

16 

A Takagi, Y Ema, S HoriiEarly adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagusGastrointest Endosc19954116770

17 

RM Sperling, JH GrendellAdenocarcinoma arising in an inlet patch of the esophagusAm J Gastroenterol19959015003

18 

M Kammori, T Ogawa, M HashimotoA case of early esophageal adenocarcinoma developed from islet patch of gastric mucosa in the cervical esophagusJpn J Gastroenterol Surg19962971721

19 

S Pai, R Deshpande, KN NareshAdenocarcinoma of cervical esophagus arising in aberrant gastric mucosaIndian J Gastroenterol1997161578

20 

C Berkelhammer, M Bhagavan, A TempletonGastric inlet patch containing submucosally infiltrating adenocarcinomaJ Clin Gastroenterol19972567881

21 

S Yamamoto, N Habu, Y ToriumiA case of primary upper esophageal adenocarcinoma in super high age arising from ectopic gastric mucosaJpn Gastroenterol Surg19973014311431

22 

GY Lauwers, GV Scott, JN VautheyAdenocarcinoma of the upper esophagus arising in cervical ectopic gastric mucosaDig Dis Sci1998439017

23 

T Noguchi, S Takeno, Y TakahashiPrimary adenocarcinoma of the cervical esophagus arising from heterotopic gastric mucosaJ Gastroenterol2001367049

24 

N Kagawa, Y Fukuda, T IshimotoA case of esophageal adenocarcinoma arising from ectopic gastric mucosa in the cervico-thoracic esophagusJpn J Surg Association200465263741

25 

T Abe, M Hosokawa, T KusumiAdenocarcinoma arising from ectopic gastric mucosa in the cervical esophagusAm J Clin Oncol2004276445

26 

JY An, YH Baik, MG ChoiPredictive factors for lymph node metastasis in early gastric cancer with submucosal invasion: Analysis of a single institutional experienceAnn Surg200724674953

27 

ML Sjoerd, JWK Fiebo, BR JohannesPrognostic factors in adenocarcinoma of the esophagus or gastroesophageal JunctionJ Clin Oncol200624434755

28 

C Alexiou, OA Khan, E BlackSurvival after esophageal resection for carcinoma: the importance of the histologic cell typeAnn Thorac Surg20068210737

29 

S Sakuramoto, M Sasako, T YamaguchiAdjuvant chemotherapy for gastric cancer S-1, an oral fluoropyrimidineN Engl J Med2007357181020

30 

W KoizumiPhase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerBr J Cancer200389220712

31 

D Cunningham, WH Allum, SP StenningPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med20063551120

32 

AD Wagner, W Grothe, J HaertingChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol20062429039

33 

P Ross, M Nicolson, D CunninghamProspective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancerJ Clin Oncol20022019962004

34 

A Webb, D Cunningham, JH ScarffeRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerJ Clin Oncol1997152617

Abstract views:
804

Views:
PDF
213
HTML
13963

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2010 Shuji Komori, Shinji Osada, Yoshihiro Tanaka, Narutoshi Nagao, Kazuya Yamaguchi, Nami Asano, Kazuhiro Yoshida

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185